Mereo Biopharma Group Stock Today
| MREO Stock | USD 4.69 0.11 2.40% |
Performance12 of 100
| Odds Of DistressLess than 8
|
Mereo BioPharma is selling at 4.69 as of the 31st of August 2024; that is 2.40% increase since the beginning of the trading day. The stock's open price was 4.58. Mereo BioPharma has only a 8 % chance of going through financial distress over the next few years and had a good performance during the last 90 days. Equity ratings for Mereo BioPharma Group are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of June 2024 and ending today, the 31st of August 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 24th of April 2019 | Category Healthcare | Classification Health Care |
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom. The company has 153.85 M outstanding shares of which 4.54 M shares are now shorted by private and institutional investors with about 4.83 trading days to cover. More on Mereo BioPharma Group
Moving against Mereo Stock
Mereo Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Denise ScotsKnight | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMereo BioPharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Mereo BioPharma's financial leverage. It provides some insight into what part of Mereo BioPharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Mereo BioPharma Group (MREO) is traded on NASDAQ Exchange in USA. It is located in One Cavendish Place, London, United Kingdom, W1G 0QF and employs 33 people. Mereo BioPharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 721.57 M. Mereo BioPharma Group conducts business under Biotechnology sector and is part of Health Care industry. The entity has 153.85 M outstanding shares of which 4.54 M shares are now shorted by private and institutional investors with about 4.83 trading days to cover.
Mereo BioPharma Group currently holds about 94.3 M in cash with (21.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.81.
Check Mereo BioPharma Probability Of Bankruptcy
Ownership AllocationMereo BioPharma Group maintains a total of 153.85 Million outstanding shares. Over half of Mereo BioPharma's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Mereo Ownership Details
Mereo Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Millennium Management Llc | 2024-03-31 | 2.2 M | |
| Integral Health Asset Management, Llc | 2024-06-30 | 1.8 M | |
| Renaissance Technologies Corp | 2024-03-31 | 1.7 M | |
| Susquehanna International Group, Llp | 2024-03-31 | 1.6 M | |
| Morgan Stanley - Brokerage Accounts | 2024-03-31 | 1.4 M | |
| Soleus Capital Management, L.p. | 2024-06-30 | 1.2 M | |
| Marshall Wace Asset Management Ltd | 2024-06-30 | 1.1 M | |
| Neos Investment Management, Llc | 2024-03-31 | 623.4 K | |
| Eversept Partners, Llc | 2024-06-30 | 496.2 K | |
| Rubric Capital Management Lp | 2024-06-30 | 15.3 M | |
| Adage Capital Partners Gp Llc | 2024-06-30 | 11.8 M |
Mereo BioPharma Historical Income Statement
Mereo Stock Against Markets
Mereo BioPharma Corporate Management
| Christine CPA | Chief Officer | Profile | |
| Bo Kara | Senior CMC | Profile | |
| Fiona Bor | Head Property | Profile | |
| Jackie Parkin | Therapy Endocrinology | Profile | |
| MBBS MD | CoFounder Strategy | Profile | |
| John Lewicki | Chief Officer | Profile |
Additional Information and Resources on Investing in Mereo Stock
When determining whether Mereo BioPharma Group offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mereo BioPharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mereo Biopharma Group Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mereo Biopharma Group Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo BioPharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.26) | Revenue Per Share 0.007 | Return On Assets (0.24) | Return On Equity (0.48) |
The market value of Mereo BioPharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo BioPharma's market value can be influenced by many factors that don't directly affect Mereo BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mereo BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.